Table 6 Antibiotic use for the top ten diagnoses among inpatients, by ATC classification
From: Antibiotic prescribing to inpatients in Limpopo, South Africa: a multicentre point-prevalence survey
Diagnosis | LRTI | SST | Proph OBGY | Neo-MP | GI | HIV | OBGY | Sepsis | CNS | BJ | Total | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antibiotic ATC classes | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | N | % |
Aminoglycosides | 4 | 3.8 | 4 | 4.5 | 0 | 0.0 | 16 | 50.0 | 3 | 12.5 | 0 | 0.0 | 0 | 0.0 | 2 | 11.1 | 1 | 8.3 | 0 | 0.0 | 30 | 7.9 |
Beta-lactam combination penicillin | 34 | 32.7 | 27 | 30.3 | 1 | 1.9 | 0 | 0.0 | 3 | 12.5 | 0 | 0.0 | 2 | 11.1 | 3 | 16.7 | 0 | 0.0 | 1 | 9.1 | 71 | 18.7 |
Carbapenems | 1 | 1.0 | 2 | 2.2 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 8 | 44.4 | 1 | 8.3 | 0 | 0.0 | 12 | 3.2 |
Glycopeptides | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 11.1 | 1 | 8.3 | 0 | 0.0 | 3 | 0.8 |
Imidazoles | 12 | 11.5 | 24 | 27.0 | 26 | 49.1 | 0 | 0.0 | 13 | 54.2 | 0 | 0.0 | 8 | 44.4 | 1 | 5.6 | 0 | 0.0 | 2 | 18.2 | 86 | 22.7 |
Macrolides | 14 | 13.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 5.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 15 | 4.0 |
Oxazolidinones | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 8.3 | 0 | 0.0 | 1 | 0.3 |
Extended spectrum penicillins | 8 | 7.7 | 10 | 11.2 | 22 | 41.5 | 16 | 50.0 | 3 | 12.5 | 0 | 0.0 | 4 | 22.2 | 0 | 0.0 | 0 | 0.0 | 5 | 45.5 | 68 | 17.9 |
Sulphonamide-trimethoprim combination | 1 | 1.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 18 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 19 | 5.0 |
3GCs | 30 | 28.8 | 22 | 24.7 | 4 | 7.5 | 0 | 0.0 | 2 | 8.3 | 0 | 0.0 | 3 | 16.7 | 2 | 11.1 | 8 | 66.7 | 3 | 27.3 | 74 | 19.5 |
Total | 104 | 100.0 | 89 | 100.0 | 53 | 100.0 | 32 | 100.0 | 24 | 100.0 | 18 | 100.0 | 18 | 100.0 | 18 | 100.0 | 12 | 100.0 | 11 | 100.0 | 379 | 100.0 |